Carlsmed, Inc. specializes in medical devices for spine surgery, highlighted by its recent Aprevo Cervical Platform. While innovation in spinal implant technology forms the company's core advantage, Carlsmed’s financial returns remain negative with significant operating losses reported through 2025. The firm maintains a credit facility capped at $50 million with Customers Bank, inclusive of term loans and revolving credit, supporting its liquidity alongside $85.8 million in year-end cash and equivalents. Moving forward, revenue milestones tied to loan terms will be critical to watch as the company navigates the competitive and regulatory regimes of the medical device space.